Tyra Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TYRA Nasdaq 2836 tyra.bio

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tyra Biosciences, Inc.

Tyra Biosciences to Participate in Upcoming Investor Conferences - Nov 5th, 2026 2:05 pm
Tyra Biosciences (TYRA) Stock Looks Rich Against Its Book Value - Oct 31st, 2026 3:14 pm
Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value - Oct 17th, 2026 1:11 am
Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks - Oct 14th, 2026 6:35 am
Raymond James Updates Healthcare Top Picks for October - Oct 1st, 2026 2:26 pm
Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? - Sep 16th, 2026 2:07 pm
Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets - Sep 16th, 2026 9:13 am
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Sep 14th, 2026 4:45 am
Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat - Sep 9th, 2026 2:54 pm
Tyra disappoints investors with bladder cancer data - Sep 9th, 2026 9:46 am
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress - Sep 9th, 2026 8:44 am
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data - Sep 9th, 2026 8:05 am
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib - Sep 9th, 2026 5:00 am
Tyra Biosciences to Present at the Cantor Global Healthcare Conference - Sep 8th, 2026 2:05 pm
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout - Sep 4th, 2026 12:25 pm
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 - Sep 4th, 2026 6:00 am
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer - Sep 1st, 2026 6:30 am
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights - Aug 4th, 2026 2:05 pm
Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data? - Jun 30th, 2026 7:07 am
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight - Jun 23rd, 2026 8:31 am